CC BY 4.0 · Synlett 2024; 35(11): 1247-1252 DOI: 10.1055/a-2211-6490
cluster
Japan/Netherlands Gratama Workshop
Applying Lessons Learned from Developing Exon Skipping for Duchenne to Developing Individualized Exon Skipping Therapy for Patients with Neurodegenerative Diseases
The author receives grant funding from the European Union, Duchenne Parent Project (Netherlands), ZonMw (Netherlands), Prinses Beatrix Spierfonds (Netherlands), Duchenne Research Fund (UK), Entrada Therapeutics, Sarepta Therapeutics, U.S. Department of Defense, Muscular Dystrophy Association (USA), and Stichting Ammodo (Netherlands).
Antisense oligonucleotides (ASOs) are short, modified pieces of DNA that are chemically modified. They can be used to induce exon skipping and treat Duchenne muscular dystrophy (DMD) patients by interfering with the splicing process so mutated dystrophin transcripts become readable allowing production of partially functional dystrophin proteins, rather than nonfunctional dystrophins. After over 2 decades of research, 4 ASOs are FDA approved for DMD, but clinical effects are suboptimal due to limited delivery to skeletal muscle. At the same time, ASOs for brain diseases result in much more functional impact, because local delivery allows higher exposure to the target tissue at a low dose and infrequent treatment regimen. This has opened the way to develop ASOs in an individualized setting, as was exemplified by the development of Milasen to treat a patient with CLN7 Batten disease.
In this perspective paper I will share my personal journey as one of the pioneers of ASO-mediated exon skipping development for DMD, currently applying expertise gained and lessons learned along the way to develop exon skipping ASOs for eligible patients with genetic brain diseases in a national and international setting.
1 Duchenne and Antisense-Mediated Exon Skipping
2 Opportunities for Treating Central Nervous System Diseases and Developing Individualized ASOs for Central Nervous System Diseases
3 Collaborative Spirit to Develop Individualized Treatments Globally
12
Heemskerk H,
de Winter C,
van Kuik P,
Heuvelmans N,
Sabatelli P,
Rimessi P,
Braghetta P,
van Ommen GJ,
de Kimpe S,
Ferlini A,
Aartsma-Rus A,
van Deutekom JC.
Mol. Ther. 2010; 18: 1210
13
Goemans NM,
Tulinius M,
van den Akker JT,
Burm BE,
Ekhart PF,
Heuvelmans N,
Holling T,
Janson AA,
Platenburg GJ,
Sipkens JA,
Sitsen JM,
Aartsma-Rus A,
van Ommen GJ,
Buyse G,
Darin N,
Verschuuren JJ,
Campion GV,
de Kimpe SJ,
van Deutekom JC.
N. Engl. J. Med. 2011; 364: 1513
23
Kim J,
Hu C,
Moufawad El Achkar C,
Black LE,
Douville J,
Larson A,
Pendergast MK,
Goldkind SF,
Lee EA,
Kuniholm A,
Soucy A,
Vaze J,
Belur NR,
Fredriksen K,
Stojkovska I,
Tsytsykova A,
Armant M,
DiDonato RL,
Choi J,
Cornelissen L,
Pereira LM,
Augustine EF,
Genetti CA,
Dies K,
Barton B,
Williams L,
Goodlett BD,
Riley BL,
Pasternak A,
Berry ER,
Pflock KA,
Chu S,
Reed C,
Tyndall K,
Agrawal PB,
Beggs AH,
Grant PE,
Urion DK,
Snyder RO,
Waisbren SE,
Poduri A,
Park PJ,
Patterson A,
Biffi A,
Mazzulli JR,
Bodamer O,
Berde CB,
Yu TW.
N. Engl. J. Med. 2019; 381: 1644
24
Kim J,
Woo S,
de Gusmao CM,
Zhao B,
Chin DH,
DiDonato RL,
Nguyen MA,
Nakayama T,
Hu CA,
Soucy A,
Kuniholm A,
Thornton JK,
Riccardi O,
Friedman DA,
El Achkar CM,
Dash Z,
Cornelissen L,
Donado C,
Faour KN. W,
Bush LW,
Suslovitch V,
Lentucci C,
Park PJ,
Lee EA,
Patterson A,
Philippakis AA,
Margus B,
Berde CB,
Yu TW.
Nature 2023; 619: 828
